CDNA Stock Overview
Engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CDNA from our risk checks.
CareDx, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.06 |
| 52 Week High | US$34.84 |
| 52 Week Low | US$7.42 |
| Beta | 1.8 |
| 11 Month Change | -6.01% |
| 3 Month Change | -28.75% |
| 1 Year Change | 124.42% |
| 33 Year Change | -49.86% |
| 5 Year Change | 5.10% |
| Change since IPO | 120.60% |
Recent News & Updates
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
Nov 05
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Sep 29Recent updates
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
Nov 05CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Sep 29CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Aug 01CareDx: Benefiting From Some Certainty
Jul 15Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
Apr 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
Mar 02CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price
Jun 29Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)
May 16CareDx: Shaking Off First-Mover Disadvantage
Oct 18CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers
Aug 08Shareholder Returns
| CDNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.2% | -7.5% | -1.2% |
| 1Y | 124.4% | 14.1% | 30.4% |
Return vs Industry: CDNA exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: CDNA exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CDNA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CDNA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 639 | John Hanna | caredx.com |
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
CareDx, Inc Fundamentals Summary
| CDNA fundamental statistics | |
|---|---|
| Market cap | US$1.18b |
| Earnings (TTM) | -US$143.56m |
| Revenue (TTM) | US$312.78m |
3.8x
P/S Ratio-8.2x
P/E RatioIs CDNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDNA income statement (TTM) | |
|---|---|
| Revenue | US$312.78m |
| Cost of Revenue | US$107.07m |
| Gross Profit | US$205.71m |
| Other Expenses | US$349.27m |
| Earnings | -US$143.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.68 |
| Gross Margin | 65.77% |
| Net Profit Margin | -45.90% |
| Debt/Equity Ratio | 0% |
How did CDNA perform over the long term?
See historical performance and comparison